Why the study?
Does the Inflation Reduction Act reduce out-of-pocket costs for guideline-directed medical therapy in Medicare Part D beneficiaries with HFrEF compared to current law?
Does the Inflation Reduction Act reduce out-of-pocket costs for guideline-directed medical therapy in Medicare Part D beneficiaries with HFrEF compared to current law?
This study estimates the impact of the Inflation Reduction Act on out-of-pocket costs for HFrEF medications under Medicare Part D.
This cross-sectional study estimates out-of-pocket costs of heart failure with reduced ejection fraction medication regimens in Medicare Part D under current law and the Inflation Reduction Act.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: